Systemic Sclerosis by Borlu, Murat & Solak, Eda Öksüm
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
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Murat Borlu and Eda Öksüm Solak
Abstract
Systemic sclerosis (SSc) is a chronic, autoimmune disease which can affect 
the blood vessels, the visceral organs, and the skin. SSc, most commonly, devel-
ops between the ages of 30 and 50, but it can be seen at any age. In terms of skin 
involvement, SSc can be classified as limited or diffuse. Its etiopathogenesis is 
still unclear. Microvascular dysfunction is thought to be followed by immunologi-
cal activation, collagen and extracellular matrix deposition, and finally fibrosis. 
Diagnosis is based on clinical presentation. Sclerosis of the metacarpophalangeal 
and/or metatarsophalangeal joints is the major diagnostic criterion, whereas sclero-
dactylia, digital ulcers (DU), and pulmonary fibrosis are the minor criteria. SSc is 
diagnosed with one major criterion or two minor criteria. Detection of autoantibod-
ies can help the diagnosis. Antinuclear antibody (ANA), anti-centromere antibody, 
anti-scl 70, RNA polymerase 1 and 3, and anti-fibrillin antibody can be found 
positive in SSc. SSc must be differentiated from all sclerosing diseases and the dis-
eases with Raynaud’s phenomenon. Visceral diseases, such as primary pulmonary 
hypertension, primary biliary cirrhosis, and infiltrative cardiomyopathy, should 
also be considered in its differential diagnosis. The main treatment goal is to target 
visceral involvement.
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1. Introduction
Systemic sclerosis (SSc) is a chronic immune-mediated connective tissue 
disease, including the skin, inner organs, and blood vessels, with heterogeneous 
multiple organ involvement whose etiology is unknown. It has two subtypes: 
diffuse and limited. Its incidence ranges from 4 to 43 million people [1–3] per year, 
with a prevalence of 88–443 million [4, 5]. It can be seen at any age, though it is 
most commonly seen in patients aged 30–50 years. The disease shows an earlier 
onset and a more severe course in black patients [6]. The incidence in women is 
three to four times higher than in men [6]. Epidemiological studies showed that 
there is a significant increase in SSc risk in people, whose first-degree relatives have 
this disease [7].
2. Pathogenesis
The pathogenesis of SSc is not fully known. Disease-triggering agents are some 
organic solvents (e.g., silica, vinyl chloride, trichloroethylene, epoxy resins, ben-
zene, carbon tetrachloride), some viral diseases (HSV5, CMV), some medications 
(bleomycin, pentazocine), and radiotherapy [8].
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Basic pathogenicities of the disease are microvascular function disorder (vascu-
lopathy) and immune activation, and the final effect of these events is progressive 
tissue fibrosis with activation of fibroblasts [9].
Vascular disease is observed earliest in SSc pathogenesis. The disease plays an 
important role in the occurrence of pulmonary artery hypertension, Raynaud’s 
phenomenon, renal damage, and digital ulcers (DU) [10–13]. Raynaud’s phenom-
enon, a typical clinical characteristic of SSc, is a finding characterized by persistent 
vasospasm and increased adhesion molecules following ischemia and reperfusion 
attacks [14]. Increased adhesion molecules trigger platelets and neutrophils that 
bind to endothelial cells and produce superoxide radicals responsible for endothelial 
cell damage [15]. In addition, an imbalance between vasoconstrictor agents such as 
endothelin-1 (ET-1) and vasodilating agents such as nitric oxide was observed in 
SSc, which plays a role in the change of vascular permeability [16]. Increased ET-1 
expression plays a role in vascular fibrosis, inflammation, and increased smooth 
muscle cell proliferation [12]. An impaired cross talk between endothelial cells and 
perivascular cells may induce an abnormal expression of endothelial growth factor 
(VEGF), TGF-β, and platelet-derived growth factor (PDGF) in SSc. This may lead 
to a disruption of peripheral vascularization, which results in fibrosis of the skin 
and internal organs [17].
It has been determined that Th2 cytokines such as IL 4, IL 5, and IL 13 are over-
secreted in SSc patients. It increases IL 4 collagen synthesis and TGF-β production. 
With IL 13, however, fibroblast activity and TGF-β stimulation are carried out 
[18]. Also, B-cells produce antibodies and carry out direct fibroblast stimulation 
via IL 6 [18].
3. Diagnostic criteria and classification
SSc is a heterogeneous disease and this disease spectrum contains different 
forms. Although the CREST syndrome (calcinosis, Raynaud’s phenomenon, 
esophageal motility disorder, sclerodactyly, telangiectasia) was first defined in 1959, 
Criteria Score
1. Skin hardening of the fingers of both hands spreading proximal to the MKF joints 9
2. Skin hardening of the fingers
• Puffy fingers 2
• Sclerodactyly (only high scores will be counted) 4
3. Fingertip lesions
• Digital ulcers 2
• Digital pitting (only high scores will be counted) 3
4. Telangiectasia 2
5. Capillary changes such as abnormal fingernails 2
6. Pulmonary arterial hypertension 2
• Interstitial lung disease (maximum 2 points) 2
7. Raynaud’s phenomenon 3
8.  SSc-related autoantibodies (anti-centromere, anti-topoisomerase I, anti-RNA 
polymerase III)
3
Table 1. 
ACR/EULAR 2013 systemic sclerosis classification criteria (adapted from source [21]).
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it does not fit any classification criteria, and since a subgroup has not been fully 
defined, it is recommended not to use it nowadays [19].
The criteria published by the American Radiology Associates (ARA) in 1980 
have been used for classification for a long time. According to this, symmetrical 
skin sclerosis in the metacarpophalangeal joint or proximal of the metatarsopha-
langeal joint is a major criterion, while sclerodactylia, digital atrophic cicatrice, and 
the loss of finger fat tissue in the distal and bilateral fibrosis in the lungs constitute 
minor criteria. Diagnosis is possible with the presence of the major criteria or two 
minor criteria [20]. The ARA criteria do not include patients with limited skin 
involvement or early SSc and do not involve capillaroscopy/autoantibody tests.
In 2013, the American College of Rheumatology/European League against 
Rheumatism (ACR/EULAR) classification criteria were defined. Sensitivity and 
specificity of these criteria were shown to be higher than the ARA criteria [21]. 
Table 1 shows the ACR/EULAR 2013 systemic sclerosis classification criteria. The 
total score is the sum of the points received from different categories. Patients 
with a score of nine or higher are classified as definitive systemic sclerosis. 
However, the use is not recommended in patients with skin thickening that does 
not involve the fingers, in the presence of scleroderma-like diseases or better clini-
cal pictures.
4. Clinical findings
4.1 Cutaneous involvement
Systemic sclerosis is divided into two subgroups, according to cutaneous 
involvement: limited systemic sclerosis and diffuse systemic sclerosis. If cutaneous 
involvement is limited to distal extremities and the face, it is classified as limited 
systemic sclerosis, and if the involvement is present in the truncus and extremities, 
it is classified as diffuse systemic sclerosis [22]. Also, systemic sclerosis sine sclero-
derma, of which 5% of SSc patients are affected, shows typical SSc symptoms but 
no fibrosis of the skin [23]. Raynaud’s phenomenon is seen in more than 90% of SSc 
patients and is triggered by exposure to cold or emotional stress. It is characterized 
by white, blue, and red discoloration after triggering and most often affects the 
hands, feet, tongue, ears, and nose [24].
Cutaneous involvement generally consists of three phases. In the first stage, the 
edematous phase, non-pitting edema, facial mask appearance, and swelling of the 
fingers can be seen. After that comes the indurative phase, where the skin hardens 
and gets a shiny and tense appearance. The last stage is the atrophic phase, charac-
terized by claw hand and sclerodactyly. Sharpening of the nose, thinning of the lips, 
vertical streaks around the mouth (Figure 1), and facial mimic loss may be seen. 
Skin lines or hyperpigmentation of skin areas exposed to trauma and depigmenta-
tion areas on the truncus, face, hand back, and leg fronts may develop. In some 
cases, the presence of depigmented areas, where perifollicular areas are preserved, 
results in an appearance of “salt and pepper” on the skin.
In systemic sclerosis disease-specific capillary dilatation, stumps and the pres-
ence of avascularity areas can be shown with nail bed capillaroscopy [25]. Sweat 
and atrophy of the sebaceous gland may lead to dry skin, flaking, and itching. 
Depending on the calcium accumulation in the skin, hard subcutaneous nodules 
may appear around the small joints of the hand (calcinosis cutis), which may open 
to the outside and become ulcers [26]. Ulcers (Figure 2) may also develop due to 
ischemia, trauma, and fibrotic tissue. Telangiectasia is commonly seen in SSc and is 
stated in the classification criteria [21].
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4.2 Gastrointestinal system involvement
Ninety percent of scleroderma patients show gastrointestinal involvement. 
Although it can involve any part of the gastrointestinal tract from the mouth to the 
anus, the esophagus is the most commonly involved area [27]. The most common 
complications of SSc in the oral cavity are microstomy and xerostomy. Symptoms 
of esophageal disease depend on dysmotility and reflux, and related to this, dys-
phagia, odynophagia, regurgitation, pyrosis, chronic cough, or hoarseness can 
occur. Stricture, Barrett’s esophagus, aspiration pneumonia, and adenocarcinoma 
may develop as complications in these patients [27, 28]. The two most common 
symptoms of SSc in the stomach are gastroparesis and gastric antral vascular ectasia 
(GAVE). A typical striped watermelon appearance is present. Iron deficiency 
anemia due to GAVE may also be seen [28]. After bacterial growth due to small 
intestinal involvement, diarrhea and malabsorption or pseudo-obstruction due 
to hypomotility and dilatation may be observed [28]. Constipation, fecal, rectal 
prolapse, spontaneous perforation, and colon infarction may develop in the colon 
and have anorectal involvement [29].
Figure 1. 
Nasal sharpening and perioral vertical streaks in a patient.
Figure 2. 
Digital ulcer in a patient.
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4.3 Pulmonary involvement
Pulmonary involvement, the most important cause of mortality and morbidity 
in SSc, may occur in the form of interstitial lung disease (ILD) or pulmonary arte-
rial hypertension (PAH) [30].
The highest risk for ILD development is within the first 5 years of the disease. 
Progressive exercise dyspnea and nonproductive cough are the most common 
symptoms. Diagnosis is placed with the help of imaging methods and pulmonary 
function tests. High-resolution computed tomography is a sensitive method in 
imaging and can show the degree of fibrosis.
Pulmonary artery hypertension affects approximately 15% of scleroderma 
patients and leads to right heart failure, and the gold standard method for the 
diagnosis of PAH is right heart catheterization with high pressure in the pulmonary 
artery [31].
4.4 Musculoskeletal involvement
The most common involvement of the musculoskeletal system in SSc are 
tendinopathy, joint contractures, and in some cases arthritis. In 45–90% of patients, 
arthralgia and arthritis of the small joints of the wrist, knees, and ankles occur [31].
Tenosynovitis and tendon ruptures are frequently detected in SSc. Tendon 
friction sound that can be detected by physical examination is caused by fibrotic 
deposits in the tendon sheath [32].
Calcinosis and acroosteolysis in the bones (resorption of terminal phalanx) can 
be seen in SSc patients. These changes are related to digital ischemia [31].
In addition, muscle weakness and pain, which mainly affects the proximal 
muscles, is another common symptom in SSc. Muscle involvement may occur in 
the form of myopathy or myositis, and patients should be evaluated from this angle 
[31]. Muscle weakness may result from nonuse, sedentary life, or joint/tendon 
involvement or sometimes as a side effect of treatment.
Although respiratory muscle involvement is not common in SSc, respiratory 
muscles may be affected in SSc-polymyositis/dermatomyositis overlap syn-
drome [31].
4.5 Cardiac involvement
Cardiac involvement in SSc can be seen in two ways: primary and secondary. 
Secondary involvement may be secondary to pulmonary arterial hypertension, 
interstitial lung disease, or kidney disease [33]. Primarily, all layers of the heart, 
conduction system, coronary vessels, and valves can be involved. Because of these 
involvements, pericardial effusion, supraventricular or ventricular arrhythmias, 
conduction disorders, valve regurgitation, myocardial ischemia, myocardial hyper-
trophy, and heart failure may develop [34].
Because myocardial findings are often faint, especially in the early stage, it is 
very difficult to detect these patients. However, when the involvement progresses 
to the symptomatic stage, the patient develops one of the poor prognostic factors 
[31]. Therefore, early diagnosis of cardiac involvement in SSc is very important. 
Electrocardiography or echocardiography is not effective in detecting cardiac fibro-
sis. Magnetic resonance imaging (MRI) is the only method that can detect cardiac 
involvement in the early stages of the disease. A cardiac MRI can show myocardial 
inflammation, fibrosis, decreased perfusion of the heart muscle, and ventricular 
dysfunction [35].
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4.6 Renal involvement
Renal involvement in scleroderma is quite common. Even though it appears 
often as mild renal dysfunction, it can also cause a severe clinical table called sclero-
derma renal crisis (SRC). The pathogenesis of SRC is not fully known, but studies 
suggest vasculopathy as a source. Corticosteroids and vasospasm-causing drugs 
(tacrolimus, cyclosporine, and cocaine) may play a role in the etiology [36]. The 
risk of SRC development increases in the presence of the autoantibodies anti-RNA 
polymerase III, anti-topoisomerase I, and anti-U3RNP [36].
Some patients show a chronic clinical table with gradual decrease in eGFR, 
increase in serum creatinine concentration, proteinuria, hematuria, and moderate 
arterial hypertension [31].
Decreased glomerular filtration rate, increased serum creatinine, hemolytic 
anemia, proteinuria, and decreased platelet count are laboratory findings indicating 
renal involvement [31].
5. Autoantibodies
Antinuclear antibodies (ANA) are 90–95% positive in SSc patients and are the 
most commonly detected autoantibody. Scleroderma-like diseases should also be 
considered in the case of ANA negativity. Anti-topoisomerase I (anti-scl 70) antibod-
ies are connected to pulmonary complications, digitals ulcers, and progressive hand 
involvement. Anti-centromere antibodies are common in limited SSc and positively 
increase the risk of pulmonary fibrosis and pulmonary hypertension. Anti-RNA 
polymerase III antibody is associated with renal crisis. Also anti-U3RNP and anti-Th/
To antibodies can be detected positively, and the anti-U3RNP antibody increases the 
risk of pulmonary artery hypertension and cardiovascular complications [37].
6. Histopathology
The diagnosis of systemic sclerosis is placed clinically; therefore biopsy is not 
recommended routinely [38]. It can be used to rule out other diseases for differen-
tial diagnosis. Histologically, excessive collagen accumulation, atrophy of pilose-
baceous and eccrine glands, subcutaneous fat loss, and lymphocytic infiltrate are 
observed. Increased collagen can compress adnexal structures, especially eccrine 
glands [38].
7. Differential diagnosis
There are many diseases that may trigger dermal sclerosis. The form and charac-
ter of skin involvement, history of underlying diseases, and chemical exposures are 
helpful factors in approaching the diagnosis of a patient with skin thickening. Some 
laboratory studies may be beneficial in verifying imaging and skin biopsy diagnosis 
[8]. Eosinophilic fasciitis, scleroderma, scleromyxedema, and nephrogenic systemic 
fibrosis are important in the differential diagnosis of SSc. SSc can be differenti-
ated from other scleroses by the presence of Raynaud’s phenomenon, typical distal 
extremity involvement, nail fold capillary findings, presence of autoantibodies, and 
internal organ involvement. While the groove mark, which is a recess caused by the 
withdrawal of subcutaneous tissues along the path of the superficial vessels, favors 
the eosinophilic fasciitis [39], the detection of monoclonal gammopathy directs 
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the diagnosis towards scleroderma or scleromyxedema (bbb). Again, if underlying 
renal failure or gadolinium exposure is detected, the first thought should be towards 
nephrogenic systemic fibrosis [40].
8. Treatment
The pathogenesis of SSc is still unclear. In recent years, advances have been made 
in the treatment of the disease, resulting in a prominent improvement in survival 
rates. The efficient treatment of complications increases the chances of success. 
Disease duration, complications, and disease activity should be taken into consid-
eration when making therapeutic decisions. The treatment is based on modifying 
agents and organ-specific drugs [41].
Peripheral vascular involvement frequently occurs as Raynaud’s phenomenon. In 
addition, digital ischemia due to digital vasculopathy, digital ulcers, and associated 
amputations may be the causes for morbidity in SSc.
Patients with Raynaud’s phenomenon should protect themselves from the cold. 
They also should not smoke and should avoid vasoconstrictor agents. Calcium 
channel inhibitors (nifedipine, diltiazem, amlodipine) should be the first choice as 
treatment [41]. Iloprost and other intravenous prostanoids can be used in cases that 
do not respond to the above. Also, phosphodiesterase type 5 (PDE5) inhibitors may 
be effective in resistant cases. Selective serotonin reuptake inhibitors, pentoxifyl-
line, prazosin, and endothelin receptor antagonists (ERA) are agents that are less 
effective and used in selected cases [42].
Early treatment of patients with digital ischemia SSc reduces the risk of morbid-
ity. Intermittent infusion of prostacyclin or analogs was found to be effective in 
the treatment of RF and ischemic digital ulcer [41]. Sildenafil and bosentan are 
recommended for the treatment of digital ulcers that developed due to unsuccessful 
treated systemic sclerosis with calcium channel blockers and prostanoid therapies 
[41]. There are also uncontrolled studies suggesting that atorvastatin, vitamin E, 
and intravenous N-acetylcysteine may be beneficial. Mesenchymal stem cell therapy 
is one of the developing methods in the treatment of DU [43].
The first choice for the treatment of pulmonary artery hypertension is phos-
phodiesterase type 5 inhibitors (e.g., sildenafil or tadalafil) or endothelin receptor 
antagonists such as bosentan and macitentan. If those are not effective, prostanoids 
may be added to the treatment [44]. Prostanoids are the first choice in severe 
cases. If there is no response, combination treatments can be applied. Recently, the 
guanylate cyclase agonist riociguat has been involved in treatment [41].
The treatment of interstitial lung disease patients is based on immunosuppres-
sive drugs. The first preferred agent is oral mycophenolate mofetil (MMF). One of 
the applied treatment regimens for nonresponsive patients is the administration 
of cyclophosphamide (CYC) orally at doses of 1–2 mg/kg/day or iv 600 mg/m2/
month. After the disease activity has been taken under control, it is recommended 
to continue treatment with azathioprine at a dose of 2.5 mg/kg/day [41]. In selected 
patients, rituximab (RTX, anti-CD20 monoclonal antibody) can be used as an alter-
native treatment [41, 45].
Immunosuppressants such as methotrexate (MTX), cyclophosphamide, and 
mycophenolate mofetil are commonly used in fibrosis of the skin [31]. If the 
treatment is unsuccessful or if these drugs cannot be used for whatever reason, 
low-dose systemic corticosteroids or rituximab may be preferred [31]. The effect of 
d-penicillamine, which has been used for many years, is controversial [46].
In systemic sclerosis, exertional dyspnea, tachycardia, and chest pain may occur 
due to myocardial involvement. Selective beta-blockers are effective in this kind 
Vascular Biology
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of symptoms [33]. If cardiac tamponade develops due to pericarditis in cardiac 
involvement, treatment becomes more difficult. The patient may not respond to 
systemic corticosteroid therapy, and drainage treatment may become necessary 
[47]. Some SSc patients may develop microvascular ischemia due to vasospasm of 
small coronary arteries and arterioles, also called cardiac Raynaud’s phenomenon. 
Nifedipine treatment is quite effective in such patients [48].
SSc patients with GI involvement of dysphagia, pyrosis, esophageal reflux, 
esophagitis, distention, abdominal pain, and diarrhea can be treated with proton 
pump inhibitors (PPI), prokinetic drugs, and intermittent antibiotics (gg). Patients 
that developed gastric antral vascular ectasia may have severe upper GI bleed-
ing. Here, supportive treatment and endoscopic treatment methods can be used. 
Surgical antrectomy becomes necessary as the last resort in resistant cases [49].
The first choice for patients with scleroderma renal crisis is a high dose of 
angiotensin receptor antagonists (ACE-I). It was determined that this treatment 
significantly decreased mortality [31]. In cases with insufficient response, angio-
tensin receptor blockers (ARB) and calcium channel blockers may be combined 
with ACE-I treatment of nitrates [31]. Beta-blockers are not recommended due to 
Organ involvement Recommendation Strength of 
recommendation
Raynaud’s phenomenon • Calcium antagonists A
• PDE-5 inhibitors A
• Prostanoids A
• Fluoxetine C
Digital ulcers • Intravenous iloprost A
• PDE-5 inhibitors A
• Bosentan* A
Pulmonary arterial 
hypertension
• ERA, PDE-5 inhibitors, riociguat B
• Intravenous epoprostenol A
• Other prostacyclin analogs (iloprost, 
treprostinil)
B
Skin and lung disease
Skin • Methotrexate A
Lung disease • Cyclophosphamide A
• HSCT A
SRC • ACE inhibitors C
• **Glucocorticoids are associated with a 
higher risk of SRC
C
Gastrointestinal disease PPI B
Prokinetic drugs C
Antibiotics L
ERA, endothelin receptor antagonists; HSCT, hematopoietic stem cell transplantation; PAH, pulmonary arterial 
hypertension; PDE-5, phosphodiesterase type 5; PPI, proton pump inhibitor; SRC, scleroderma renal crisis; SSc, 
systemic sclerosis; RP, Raynaud’s phenomenon.
*Treats and reduces the formation of new ulcers.
**Blood pressure and renal function should be carefully monitored in SSc patients treated with glucocorticoids.
Table 2. 
The updated EULAR recommendations for treatment of systemic sclerosis.
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their vasoconstriction enhancing effects. Hypotension should be avoided, and close 
monitoring should be performed for patients using systemic steroids since they 
significantly increase the risk [50].
The updated EULAR recommendations for the treatment of systemic sclerosis 
are summarized in Table 2.
9. Result
As a result, we should not forget that systemic sclerosis is a chronic disease that 
can cause serious morbidity and mortality and that placing a diagnosis can be dif-
ficult from time to time. The disease does not have a specific treatment. The patient 
should be evaluated according to involved systems and clinical table. In addition, 
early diagnosis and early initiation of treatment increase the chances of efficacy. 
A better understanding of the pathogenesis may lead to the development of more 
successful and specific treatment methods.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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